Key result
Critically ill COVID-19 patients had significantly larger basal RV diameter (39.93 vs 38.67, p=0.034) and lower TAPSE values compared to clinically stable patients.
Why the study?
Despite risks of personnel exposure, echocardiography can guide management in cardiac COVID-19 involvement, but the role of transthoracic and speckle-tracking echocardiography in critically ill patients needed evaluation.
Does transthoracic echocardiography predict clinical deterioration and detect myocardial changes after remdesivir treatment in COVID-19 patients?
Observational
No
Does transthoracic echocardiography predict clinical deterioration and detect myocardial changes after remdesivir treatment in COVID-19 patients?
Absolute Event Rate: 39.93% vs 38.67%
p-value: p=0.034
Transthoracic and speckle-tracking echocardiography can predict disease severity and detect improvements in right ventricular function following remdesivir treatment in COVID-19 patients.
Supports bedside TTE/STE for assessing cardiac involvement and severity in critical COVID-19; leaves open whether routine use alters outcomes.
Background: Coronavirus disease 2019 (COVID-19) is a contagious respiratory disease that resulted from infection with a new coronavirus (SARS-CoV-2). Despite the limitations related to risk of performing personnel exposure, echocardiography can be a very useful tool for guiding management with various finding related to the cardiac COVID involvement. The aim of this study is to determine the role of transthoracic as well as speckle-tracking echocardiography in clinical assessment of critically ill COVID-19 patients. Method: A prospective study in which COVID-19 positive patients, admitted to quarantine of Minia University Hospital in the period from December 2019 to December 2020, underwent transthoracic echocardiography initially then parameters were compared according to clinical deterioration. transthoracic echocardiography and speckle tracking echocardiograghy also were done to critically ill patients before and after remedesivir treatment. Results: Significant differences in TAPSE values were observed between group I and group II with mean± SD: 14.85 ± 3.29 and 19.35 ± 4.01, respectively. Also, significant larger basal RV diameter in critically ill patients (mean±SD: 39.93 ± 3.08) vs (mean±SD: 38.67 ± 2.82) in clinically stable patients (p value: 0.034). all TTE and STE used parameters showed highly significant improvement in RV systolic and diastolic dysfunction after treatment with remedesivir therapy. Conclusion: Echocardiograghy plays a crucial role in COVID-19 management. 2D TTE can be useful in predicting disease severity. Both 2D TTE and speckle tracking accurately diagnose cardiac involvement of critically ill COVID-19 patients; detect myocardial changes through course of treatment.
No takes yet. Share an insight, caveat, or question.
Abdelrasoul et al. (2022) conducted an observational in COVID-19. Critical illness vs. Clinically stable patients was evaluated on Basal RV diameter (p=0.034). Critically ill COVID-19 patients had significantly larger basal RV diameter (39.93 vs 38.67, p=0.034) and lower TAPSE values compared to clinically stable patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: